HOME
COMPANY
Partners
Executive Summary
PEOPLE
Kees Groen, CFO
Victor van Beusechem, CSO
Wenliang Dong, CEO
PIPELINE
Technology
ORCA-010
P53 Functions
RNA Interference
Scientific Publications
HORIZON2020
NEWS
CONTACT
HOME
COMPANY
Partners
Executive Summary
PEOPLE
Kees Groen, CFO
Victor van Beusechem, CSO
Wenliang Dong, CEO
PIPELINE
Technology
ORCA-010
P53 Functions
RNA Interference
Scientific Publications
HORIZON2020
NEWS
CONTACT
Posted by
admin
| June 18, 2014
|
Uncategorized
|
No Comments
0
https://www.hpshospitales.com/2018/05/21/faringitis-aguda/
Recent Posts
ORCA Therapeutics Announces Treatment of First Patient in Phase I/IIa study
ORCA Therapeutics receives approval from Health Canada to initiate a Phase I/IIa study with its oncolytic adenovirus ORCA-010 in treatment-naïve prostate cancer patients.
(no title)
Recent Comments
Archives
February 2020
July 2019
June 2014
Categories
Uncategorized
Meta
Log in
Entries feed
Comments feed
WordPress.org
Navigation
Executive Summary
People
Technology
Approval Health Canada
Contact
